Navigation Links
New therapy for HIV treatment
Date:7/29/2008

Millions of people world-wide who have contracted a highly resistant strain of the HIV virus could benefit from a new drug to treat the infection.

Research co-authored by the University of New South Wales' (UNSW) National Centre in HIV Epidemiology and Clinical Research (NCHECR) shows that the majority of patients who have not responded to traditional treatments have had good results from a new combination therapy.

The drug raltegravir is already available in Australia and was listed on the Pharmaceutical Benefits Scheme on July 1st, with clinical trials showing that it is safe, effective and with minimal side-effects when used with other anti-HIV medicines.

The study, which has been published in the New England Journal of Medicine, shows the raltegravir effectively lowers the amount of virus in the blood to undetectable levels in 62 percent of people taking it in combination with other anti-HIV medicines.

Only one in three people who received a placebo plus other anti-HIV medicines had the amount of virus in the blood reduced to similar levels.

"This is the first drug in a new class of antiretroviral drugs called integrase inhibitors," said UNSW Professor David Cooper AO, the Director of NCHECR .

"The drug has a different mechanism of action, is very potent, seems very safe and has helped patients who have a virus that is resistant to older drugs and classes," said Professor Cooper.

"It initially will be used in developed countries, but hopefully, it will be made available at cheaper prices for patients in developing countries who are facing the same problems," said Professor Cooper.

The results were based on analyses of viral load reductions and CD4 cell count increases. A high CD4 cell count is crucial for a healthy immune system.

Professor Cooper said the efficacy shown at 48 weeks of treatment was consistent with observations at 24 weeks, indicating that the drug in combination has a durable effect.

The study shows the drug is well-tolerated by patients. It showed that only 0.9 percent of those receiving raltegravir discontinued therapy due to side-effects including nausea and headaches.


'/>"/>

Contact: Susi Hamilton
susi.hamilton@unsw.edu.au
61-293-851-583
University of New South Wales
Source:Eurekalert

Related medicine news :

1. Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans
2. Erectile dysfunction drugs allowed more chemotherapy to reach brain tumors in laboratory study
3. CSHL scientists correlate enzyme expression levels with chemotherapy drug response
4. D-cycloserine may improve behavioral therapy treatment for anxiety
5. Tx Xchange Launches Web-Based Solution for Physical Therapy and Rehabilitation Providers to Address Demands of Healthcare Consumerism
6. LSUHSC study finds high-dose HBO2 therapy extends survival window after cardiopulmonary arrest
7. Treating rare breast cancer with radiation therapy may lower recurrence rate
8. Medicare Modernization Act not associated with major changes in access to chemotherapy
9. Hormone Therapy Shows Little Benefit Against Prostate Cancer
10. Study points to cocktail therapy for Alzheimers
11. Global Med Technologies(R) Announces U.S. Release of Proven Tissue and Cellular Therapy Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2017)... ... 2017 , ... Medical lab testing through hospitals and other traditional ... test will take days to arrive to the end customer, having to travel through ... their lab tests, bypassing the cost and delay of traditional means. Now all employees ...
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at global business ... recognized globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, strongly ... to sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice are ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa Orthopaedics ... Petaluma, located at 167 Lynch Creek Way. The Petaluma office features three comfortable ... and rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons ...
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® and ... longer use or need, from clothes to couches to dressers and bicycles. Roadie — ... them to the nearest Goodwill donation center through February 28th. , “January is ...
(Date:1/20/2017)... ... ... Bionic Sports Nutrition LLC, an American company devoted to developing high-quality nutritional supplements for ... Show in Hilton Head, SC. , Bionic Sports Nutrition manufactures its entire line ... all clients at reasonable prices. At the ECRM trade show, it had a unique ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... Jan. 20, 2017 ARMO BioSciences, Inc., a ... on the Company,s lead investigational immuno-oncology drug AM0010 (PEGylated ... the American Society of Clinical Oncology (ASCO), taking place ... "AM0010 induces the expansion ... T cells in the blood and tumors of ...
(Date:1/21/2017)... -- Research and Markets has announced the addition of ... Route Of Administration, End User - Forecast to 2025" report ... ... a CAGR of around 7.8% over the next decade to reach ... analyzes the global markets for Advanced Drug Delivery across all the ...
(Date:1/20/2017)... -- Research and Markets has announced the addition ... BMP, BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver ... - 2024" report to their offering. ... The global clinical laboratory testing market ... Introduction of innovative solutions on the grounds of maximum efficiency and ...
Breaking Medicine Technology: